

GIMEMA AML2120

A retrospective and prospective multicentre observational study for the evaluation of incidence of familial AML/MDSs in patients with myeloid neoplasms (AML/MDS)

Contatti: Monia Marchetti monia.marchetti@uniupo.it

Sindromi target:

Principali Criteri Inclusione:

Familiarity for myeloid neoplasm is suspected when the patient affected by AML/MDSs presents:

- a first-or second-degree family member who has a diagnosis of acute leukemia (AML or ALL), or MDSs, or other myeloid neoplasms;
- a first-or second-degree family member who has a diagnosis of other hematologic neoplasms;
- a first-or second-degree family member who has a diagnosis of solid tumor that has arisen in age < 40 years;
- presence of signs, symptoms or laboratory tests compatible with one of the known syndromes with germinal susceptibility to AML/MDSs